Opendata, web and dolomites

MITOPOMPE SIGNED

Targeting mitochondrial defects and oxidative stress in Pompe Disease: from pathogenesis to therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MITOPOMPE project word cloud

Explore the words cloud of the MITOPOMPE project. It provides you a very rough idea of what is the project "MITOPOMPE" about.

defects    cardiomyopathy    perform    competent    enzyme    boost    tested    functionally    dependent    neurological    interventions    mutations    buffering    sequencing    mitochondrial    neuromuscular    acid    apoptosis    gaa    caused    active    brain    accordingly    transcriptomic    calcium    mitocatalase    synaptic    pathology    avenues    mtgsh    missing    dysfunction    muscular    complemented    respiratory    mitochondria    alpha    involvement    ko    expertise    motor    rescue    pd    pharmaceutical    depending    interacting    cellular    function    glucosidase    amounts    organelle    therapy    dr    aav    stress    signaling    gene    combined    rna    group    lysosomal    neuronal    pompe    fighting    lsd    extensive    oxidative    phenotypes    phosphorylation    pathophysiology    storage    antioxidants    transmission    therapeutic    treat    full    little    disease    central    synapses    model    tissues    nrf2    therapies    mitoq    potentially    severity    disorders    treatment    neuron    mingozzi    atp    reversal    heavily    point    cell    muscle    weakness    evident    nervous    everyday    regulated    functional    mouse    lsds   

Project "MITOPOMPE" data sheet

The following table provides information about the project.

Coordinator
ASSOCIATION GENETHON 

Organization address
address: RUE DE L INTERNATIONALE 1 BIS
city: EVRY
postcode: 91002
website: www.genethon.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 173˙076 €
 EC max contribution 173˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASSOCIATION GENETHON FR (EVRY) coordinator 173˙076.00

Map

 Project objective

The central role of ATP production by oxidative-phosphorylation, together with calcium buffering and apoptosis, makes mitochondria an organelle interacting with many processes within the cell. Neuronal and muscular tissues require high amounts of ATP to perform their everyday function, therefore are heavily dependent on mitochondrial function. Neuromuscular synapses are of particular importance since synaptic transmission is a highly regulated process which requires active and functionally competent mitochondria. Accordingly, mitochondrial involvement is becoming increasingly evident in is Lysosomal Storage Disorders (LSDs) along with neurological pathology. Over the past several years Dr. Mingozzi’s group has built extensive expertise in Pompe Disease (PD), an LSD which is caused by mutations in the enzyme acid α-glucosidase (GAA). Muscle weakness, cardiomyopathy, respiratory failure, central nervous system and more specifically motor-neuron defects are observed depending on the severity of the disease. Little is known about the role of mitochondria in the pathophysiology of PD and interventions aimed at addressing mitochondrial defects in PD is currently missing. The aim of this proposal is to characterize the mitochondrial dysfunction in the Gaa KO mouse model of PD. This to assess potential rescue of such phenotypes by AAV-based GAA gene therapy complemented with therapeutic interventions targeted to treat and boost mitochondrial function by fighting against oxidative stress. Two mitochondrial treatment approaches; (i) pharmaceutical antioxidants, e.g. mitoQ or mtGSH and (ii) AAV based approaches; AAV-Nrf2 and AAV-mitoCatalase will be tested. Combined therapies with the AAV-GAA treatment will aim to reach full rescue of the muscle and brain pathology and functional reversal of mitochondrial defects. Transcriptomic changes will also be analyzed by RNA sequencing to investigate cellular signaling changes which will potentially point to novel therapeutic avenues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MITOPOMPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MITOPOMPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

DEF2DEV (2019)

Identification of the mode of action of plant defensins during root development and plant defense responses.

Read More  

MemoryAggregates (2020)

Mechanism of Whi3 Aggregation and its Age-dependent Malfunction

Read More  

BIOplasma (2019)

Use flexible Tube Micro Plasma (FµTP) for Lipidomics

Read More